These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 23146289)

  • 21. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
    Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
    Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it Fabry disease?
    Schiffmann R; Fuller M; Clarke LA; Aerts JM
    Genet Med; 2016 Dec; 18(12):1181-1185. PubMed ID: 27195818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo mutation in a male patient with Fabry disease: a case report.
    Iemolo F; Pizzo F; Albeggiani G; Zizzo C; Colomba P; Scalia S; Bartolotta C; Duro G
    BMC Res Notes; 2014 Jan; 7():11. PubMed ID: 24398019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
    Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
    J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease.
    Colomba P; Nucera A; Zizzo C; Albeggiani G; Francofonte D; Iemolo F; Tuttolomondo A; Pinto A; Duro G
    Clin Biochem; 2012 Jul; 45(10-11):839-41. PubMed ID: 22465271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
    Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
    Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The frequency of Fabry disease with the E66Q variant in the α-galactosidase A gene in Japanese dialysis patients: a case report and a literature review.
    Kikumoto Y; Sugiyama H; Morinaga H; Inoue T; Takiue K; Kitagawa M; Saito D; Takatori Y; Kinomura M; Kitamura S; Akagi S; Sada K; Nakao K; Maeshima Y; Kitayama H; Makino H
    Clin Nephrol; 2012 Sep; 78(3):224-9. PubMed ID: 22874111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
    Ge W; Wei B; Zhu H; Miao Z; Zhang W; Leng C; Li J; Zhang D; Sun M; Xu X
    Int J Neurosci; 2017 May; 127(5):448-453. PubMed ID: 27211852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
    Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
    Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Genetic and clinical study of three Chinese pedigrees with Fabry disease].
    Tian ML; Yan YL; Xiong JC; Liu XX; Yang Y; Hu ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):185-8. PubMed ID: 23568732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
    Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
    Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel A97P amino acid substitution in alpha-galactosidase A leads to a classical Fabry disease with cardiac manifestations.
    Kimura K; Sato-Matsumura KC; Nakamura H; Onodera Y; Morita K; Enami N; Shougase T; Ohsaki T; Kato M; Takahashi T; Yamaguchi Y; Shimizu H
    Br J Dermatol; 2002 Sep; 147(3):545-8. PubMed ID: 12207598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.